Pular para o conteúdo principal
Ranking Invest

IKT - Inhibikase Therapeutics, Inc.

Segmento: HealthcareInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Análise Ranking Invest

Valor de Mercado
$ 226.05 Mi
IVR
0.10Índice proprietário de comparação relativa: 0,10.
IVR2
-0.58Leitura proprietária complementar: -58%.
MLL
-0.58Leitura proprietária complementar: -58%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 153.33 Mi

L4T

-$ 60.64 Mi

Indicadores Básicos

ROE

-39.55%

Índices de Previsibilidade

Receita Líquida

G0.96

Lucro

C0.36

Margem

D0.98

Índices de Tendência

Receita Líquida

E-7.34

Lucro

G-10.57

Margem

B7.07

Índices de Endividamento

DIV/PAT

0.00

DIV/L4T

0.00

Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.